Total trials
95
Active
18
Phase 3
4
Total enrollment
224,803
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Amoxicillin-Clavulanate 400 Mg-57 Mg/5 mL Oral Powder for Reconstitution | — | — | — | — | — | 1 | |
| Fasudil | — | — | — | — | — | 1 | |
| Verteporfin | — | — | — | — | — | 1 |
Next readouts
- 2025-12-31
- 2028-01-01
- 2028-04-30
Top conditions
- Coronary Artery Disease5
- Alzheimer Disease4
- Macular Holes4
- Dementia4
- Macular Hole3
- Mild Cognitive Impairment3
- Heart Failure3
- Myocardial Infarction3
Frequently asked questions about Helse Stavanger HF
- How many clinical trials does Helse Stavanger HF have on ClinicalTrials.gov?
- Helse Stavanger HF is listed as the lead sponsor on 95 clinical trials in ClinicalTrials.gov, 18 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Helse Stavanger HF's trials are in Phase 3?
- 4 of Helse Stavanger HF's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Helse Stavanger HF focus on?
- Helse Stavanger HF's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Alzheimer Disease, Macular Holes, Dementia, Macular Hole.
- When are Helse Stavanger HF's next clinical trial readouts?
- Helse Stavanger HF has 3 upcoming primary-completion readouts tracked here; the soonest is “Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy”, expected around 2025-12-31.